BRIEF published on 03/27/2026 at 08:20, 5 months 4 days ago Vetoquinol Reports Stable 2025 Financial Performance Amid Market Volatility Financial Performance Strategic Expansion Net Cash Position Essential Products Vetoquinol 2025
BRIEF published on 03/27/2026 at 08:20, 5 months 4 days ago Vetoquinol: 2025 Annual Results Profitability Product Mix VETOQUINOL 2025 Results Essential Products
PRESS RELEASE published on 03/27/2026 at 08:15, 5 months 4 days ago Inside Information / News release on accounts, results Vetoquinol reports 2025 annual results showing €525.7m in sales (+0.2%), highlighting growth in Essential products and improved profitability Profitability Sales Growth VETOQUINOL Essential Products 2025 Annual Results
BRIEF published on 10/28/2025 at 17:50, 10 months 2 days ago Vetoquinol Reports 9-Month Sales Decline, Despite Essential Product Growth Sales Decline Currency Impact Regional Performance VETOQUINOL Essential Products
PRESS RELEASE published on 10/28/2025 at 17:45, 10 months 2 days ago Quarterly financial reporting / Third quarter financial report Vetoquinol reports 9-month sales of €384 million, down 3.5% on a reported basis but up 0.7% excluding currency impacts and range simplification. Essential products show growth Operating Profitability Organic Growth VETOQUINOL Essential Products 9-month Sales
BRIEF published on 09/11/2025 at 17:50, 11 months 19 days ago Vetoquinol posts stable results in the first half of 2025 Treasury Half-year Results Turnover VETOQUINOL Essential Products
BRIEF published on 04/25/2025 at 10:03, 1 year 4 months ago Vetoquinol's Q1 2025 Financial Report Shows Mixed Results Market Growth Q1 2025 Financials Vetoquinol Sales Essential Products Rationalization Program
PRESS RELEASE published on 04/25/2025 at 09:58, 1 year 4 months ago Quarterly financial reporting / First quarter financial report Vetoquinol reports €85m sales for Q1 2025, with growth in Essential products sales. Strong performance outside USA, Europe up by 3%, Americas by 4%, Asia-Pacific by 25% Sales Growth VETOQUINOL Q1 2025 Essential Products
BRIEF published on 08/05/2024 at 20:03, 2 years ago Reporting on capital and voting rights - July 2024 Share Capital Voting Rights AMF Financial Transparency VETOQUINOL
Published on 08/31/2026 at 15:00, 1 hour 13 minutes ago Super Copper Featured at OTC Markets' Virtual Investor Conference, Presentation Replay Now Available
Published on 08/31/2026 at 14:30, 1 hour 43 minutes ago While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
Published on 08/31/2026 at 13:30, 2 hours 43 minutes ago Nextech3D.ai Delivers 101% Revenue Growth in Fiscal Q1 2027 as AI-Powered Event Platform Accelerates
Published on 08/31/2026 at 15:40, 33 minutes ago EQS-Adhoc: SCP Standard Capital Partners AG expects to realize a book gain of approximately EUR 35 million from the acquisition of VANEA Technologies GmbH and Nocturne Technologies GmbH
Published on 08/31/2026 at 15:10, 1 hour 3 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 08/31/2026 at 15:08, 1 hour 5 minutes ago Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 08/31/2026 at 15:07, 1 hour 6 minutes ago Form 8.3 - The Vanguard Group, Inc.: Rotork plc
Published on 08/31/2026 at 12:00, 4 hours 13 minutes ago Capital increase through exercise of subscription rights
Published on 08/31/2026 at 07:00, 9 hours 13 minutes ago Biophytis strengthens its financial position and extends its cash runway into Q1 2027
Published on 08/26/2026 at 18:02, 4 days 22 hours ago Altareit: Altarea press release regarding the Primonial matter
Published on 08/26/2026 at 18:00, 4 days 22 hours ago Altarea: Comprehensive settlement agreement reached, ending the dispute between Altarea and the shareholders of the Praemia group (formerly Primonial group)
